Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Pei Li Teh & Callum McCulloch
  • December 3, 2019
  • Webinars

Webcast: Portfolio analysis - Go/No-go decisions

Webcast: Portfolio analysis - Go/No-go decisions

When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset. Watch this webcast in which Research Partnership's Pei Li Teh and Callum McCulloch (who are both from our Singapore office) discuss how market research insights allow you to make confident go/no-go decisions in portfolio planning.

read more »

  • Posted by Julie Denny
  • November 18, 2019
  • News

New appointments in our UK headquarters

New appointments in our UK headquarters

Research Partnership is delighted to announce new appointments in our UK headquarters. Aiyaz Mohammed joins as Associate Director in Therapy Watch, Tilly Lowkis joins as Business Development Manager and Apriya Rathour joins as Business Development Executive. We also welcomed an intake of 4 new Graduates to the UK office.
 

read more »

  • Posted by Wan Ling Neo & Ethel Gay
  • November 7, 2019
  • Webinars

Webcast: Portfolio analysis - Tracking for success

Webcast: Portfolio analysis - Tracking for success

Portfolio Analysis and Optimization looks at how honing strategy across multiple agents in the same therapeutic category leads to marketing success. As pharmaceutical companies simultaneously develop and in-license multiple products that can cost millions of dollars, portfolio management is about selecting how to allocate resources and marketing efforts across multiple assets. This has significant impact on the bottom line. 

read more »

  • Posted by Rachel Howard
  • October 23, 2019
  • Articles

Market access in Brazil: All eyes on Spinraza

Market access in Brazil: All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

read more »

How we helped our client identify where to play and how to win for their hospital product in India

How we helped our client identify where to play and how to win for their hospital product in India

Our client has a hospital care portfolio which is marketed globally. Despite a low per capita use of the product in India, the annual growth rate of usage is among the highest in the world. It was therefore critical for our client to understand which channels they should focus on (where to play) and what points of differentiation would enable them to gain market share in those chosen channels (how to win).
 

read more »